Suppr超能文献

抗利尿激素对尿钙排泄的调节

Regulation of urinary calcium excretion by vasopressin.

作者信息

Anastasio Pietro, Trepiccione Francesco, De Santo Natale Gaspare, Capasso Giovambattista, Viggiano Davide, Capolongo Giovanna

机构信息

Department of Translational Medical Sciences, University of Campania 'L.Vanvitelli', Naples, Italy.

BIOGEM, Ariano Irpino, Italy.

出版信息

Clin Kidney J. 2020 Sep 16;13(5):873-877. doi: 10.1093/ckj/sfaa134. eCollection 2020 Oct.

Abstract

BACKGROUND

The antidiuretic hormone (ADH) or arginine vasopressin (AVP) regulates the body's water balance. Recently, modifications in AVP levels have been related to osteoporosis during ageing and microgravity/bed rest. Therefore the present study was devised to assess whether the absence of AVP, as in patients with central diabetes insipidus (CDI), modulates renal calcium excretion.

METHODS

We retrospectively analysed data from 12 patients with CDI with measured 24-h urinary excretion levels of calcium. Data were available at the moment of the diagnosis when patients were drug-free and after therapy with dDAVP, an analog of AVP. Hypercalciuria was defined as 24-h urinary Ca >275 mg/day in males and >250 mg/day in females and a urinary calcium (Ca):creatinine (Cr) ratio >0.20 mg/mg.

RESULTS

Untreated CDI patients had a daily urinary Ca excretion of 383 ± 47 mg/day and a urinary Ca:Cr ratio of 0.26 ± 0.38 mg/mg. The urine osmolarity significantly increased after the administration of dDAVP by 210% and the urinary flow decreased by 72%. Furthermore, the estimated glomerular filtration rate (eGFR) increased by 7%, which did not reach statistical significance. dDAVP treatment did not significantly modify the urinary Ca concentration; however, the daily calcium excretion and the urinary Ca:Cr ratio were significantly decreased (160 ± 27 mg/day and 0.11 ± 0.02 mg/mg, respectively).

CONCLUSIONS

Patients with CDI show hypercalciuria even though urine is more diluted than normal controls, and dDAVP reverses this effect. These data support the intriguing relationship between AVP and osteoporosis in ageing and microgravity/bed rest.

摘要

背景

抗利尿激素(ADH)或精氨酸加压素(AVP)调节人体的水平衡。最近,AVP水平的改变与衰老以及微重力/卧床休息期间的骨质疏松症有关。因此,本研究旨在评估中枢性尿崩症(CDI)患者中AVP缺乏是否会调节肾钙排泄。

方法

我们回顾性分析了12例CDI患者的数据,这些患者测量了24小时尿钙排泄水平。数据来自诊断时患者未使用药物时以及使用AVP类似物去氨加压素(dDAVP)治疗后。高钙尿症定义为男性24小时尿钙>275mg/天,女性>250mg/天,且尿钙(Ca):肌酐(Cr)比值>0.20mg/mg。

结果

未经治疗的CDI患者每日尿钙排泄量为383±47mg/天,尿钙:肌酐比值为0.26±0.38mg/mg。给予dDAVP后,尿渗透压显著升高210%,尿流量降低72%。此外,估计肾小球滤过率(eGFR)增加了7%,但未达到统计学显著性。dDAVP治疗未显著改变尿钙浓度;然而,每日钙排泄量和尿钙:肌酐比值显著降低(分别为160±27mg/天和0.11±0.02mg/mg)。

结论

CDI患者即使尿液比正常对照更稀释也会出现高钙尿症,而dDAVP可逆转这种效应。这些数据支持了AVP与衰老以及微重力/卧床休息期间骨质疏松症之间的有趣关系。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验